Official Title
CRI and Continuous Assessment of Hemodynamic Compensation to Guide Fluid and Pressor Management in Severely Ill Patients With COVID-19
Brief Summary

The FDA has approved the CipherOx CRI T1 Tablet for use in subjects aged 19-36, and that this study aims to evaluate the device in subjects aged outside of this range and is being used off label. The FDA determined the Cipher OX CRI T1 Tablet to be a class II device in 2016, and additional research has been done since the FDA determination to further support the use of the device outside of its current labeling.

Enrolling by invitation

Device: CRI management
Patients in the CRI cohort will be monitored with the goal to maintain their supine CRI values 0.9 - 0.7 (mean 0.8).
CRI Monitoring/Management

Eligibility Criteria

Inclusion Criteria:

Eligible patients will be those who are: - COVID-19 positive; - Ages > 18 and < 70 years old; - Require > 2 liters of oxygen by nasal cannula to maintain SpO2 > 90%; - Are admitted to the sixth floor at University Hospital, on one of two designated Hospitalist services (approximately 16 COVID-19 positive patients/service).

Exclusion Criteria: - COVID-19 negative - Age 70 years - On

Eligibility Gender
Eligibility Age
Minimum: 18 Years~Maximum: 70 Years
United States

University of Colorado
Aurora, Colorado, 80045

Steven L Moulton, MD
Principal Investigator
Children's Hospital Colorado

University of Colorado, Denver
Children's Hospital Colorado
NCT Number
Compensatory Reserve Index